GSK becomes Flagship's latest partner in $7B biobucks respiratory, immunology pact

Earlier this month, Flagship Pioneering hinted that another Big Pharma may soon join its growing fleet of collaborators. Now, GSK has sailed into view.

The British drugmaker and the venture creation firm will put a combined $150 million upfront towards a respiratory and immunology-focused research project, which will involve Flagship’s portfolio of over 40 biopharma companies. The goal is to identity up to 10 novel medicines and vaccines, for which GSK will have an exclusive option to take forward for further clinical development.